Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Healthcare picks: After CPH, I pick Viemed (VMD)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(11)
•••
Post by stockfyon Jun 10, 2021 5:20am
314 Views
Post# 33360732

Healthcare picks: After CPH, I pick Viemed (VMD)

Healthcare picks: After CPH, I pick Viemed (VMD)Unlike many investors including the clueless analyst from Stifel Justin Keywood, I was very bullish on CPH at C$0.80 and C$0.90 just a few months ago and I also posted facts on this board why I was bullish on CPH at those price levels. These facts and reasons were from CPH's press releases and reports. Zero speculation. CPH is at C$1.55 now.

My new pick from the healthcare sector is Viemed Healthcare (VMD) now at C$9.

VMD has a pristine balance sheet and is dirt cheap now at C$9 trading just 7 times its 2021 adj. EBITDA and 1.5 times its 2021 revenue.

VMD also has many catalysts ahead including many growth initiatives, both organic and inorganic. These are facts. Read the latest Conference Call to see these facts and growth initiatives. The CC is posted on Seeking Alpha.



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities